DK1150959T3 - Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed - Google Patents
Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighedInfo
- Publication number
- DK1150959T3 DK1150959T3 DK00982255T DK00982255T DK1150959T3 DK 1150959 T3 DK1150959 T3 DK 1150959T3 DK 00982255 T DK00982255 T DK 00982255T DK 00982255 T DK00982255 T DK 00982255T DK 1150959 T3 DK1150959 T3 DK 1150959T3
- Authority
- DK
- Denmark
- Prior art keywords
- celecoxib
- amorphous
- drug substance
- solid state
- state form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16985699P | 1999-12-08 | 1999-12-08 | |
US09/730,663 US6964978B2 (en) | 1999-12-08 | 2000-12-06 | Solid-state form of celecoxib having enhanced bioavailability |
PCT/US2000/032435 WO2001042221A1 (en) | 1999-12-08 | 2000-12-06 | Solid-state form of celecoxib having enhanced bioavailability |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1150959T3 true DK1150959T3 (da) | 2008-06-02 |
Family
ID=26865450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00982255T DK1150959T3 (da) | 1999-12-08 | 2000-12-06 | Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed |
Country Status (20)
Country | Link |
---|---|
US (3) | US6964978B2 (da) |
EP (1) | EP1150959B1 (da) |
JP (1) | JP2004500358A (da) |
CN (1) | CN1376146B (da) |
AT (1) | ATE387431T1 (da) |
AU (1) | AU784572B2 (da) |
BR (1) | BR0008058A (da) |
CA (1) | CA2362673A1 (da) |
CY (1) | CY1107389T1 (da) |
DE (1) | DE60038162T2 (da) |
DK (1) | DK1150959T3 (da) |
EA (1) | EA003612B1 (da) |
ES (1) | ES2299441T3 (da) |
HU (1) | HUP0201450A3 (da) |
IL (2) | IL144761A0 (da) |
NO (1) | NO320844B1 (da) |
NZ (1) | NZ513964A (da) |
PL (1) | PL203262B1 (da) |
SK (1) | SK12682001A3 (da) |
WO (1) | WO2001042221A1 (da) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74539C2 (en) * | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
CN1376146B (zh) * | 1999-12-08 | 2011-04-06 | 法马西亚公司 | 提高了生物利用率的雪列柯西的固态形式 |
JP2003518485A (ja) | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | 向上された薬物濃度を与える医薬組成物 |
US6589557B2 (en) | 2000-06-15 | 2003-07-08 | Acusphere, Inc. | Porous celecoxib matrices and methods of manufacture thereof |
US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
AR030382A1 (es) * | 2000-08-18 | 2003-08-20 | Yamanouchi Pharma Tech Inc | Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida |
JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
CA2474838C (en) | 2002-02-01 | 2009-01-06 | Pfizer Products Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
WO2004026235A2 (en) * | 2002-09-20 | 2004-04-01 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
AU2003213719A1 (en) * | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
US6864373B2 (en) * | 2002-05-13 | 2005-03-08 | Pharmacia Corporation | Stable amorphous celecoxib composite and process therefor |
AU2003243699B2 (en) | 2002-06-21 | 2009-01-15 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
WO2004047752A2 (en) * | 2002-11-26 | 2004-06-10 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
EP2339328A3 (en) | 2002-12-30 | 2011-07-13 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of celecoxib |
US20040156894A1 (en) * | 2003-02-07 | 2004-08-12 | Grother Leon Paul | Use of edible acids in fast-dispersing pharmaceutical solid dosage forms |
JP2007524596A (ja) * | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
ATE540671T1 (de) | 2003-08-04 | 2012-01-15 | Bend Res Inc | Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien |
US20070060629A1 (en) * | 2003-10-17 | 2007-03-15 | Yasuhiro Imanishi | Large conductance calcium-activated k channel opener |
WO2005065657A2 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
JP2007517015A (ja) * | 2003-12-31 | 2007-06-28 | ファイザー・プロダクツ・インク | 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物 |
FR2879075B1 (fr) * | 2004-12-15 | 2007-01-19 | Adisseo France Sas Soc Par Act | Procede de preparation de granules de principe actif hydrophile par extrusion |
FR2881049B1 (fr) * | 2005-01-24 | 2008-12-26 | Vetoquinol Sa Sa | Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation |
ATE480229T1 (de) * | 2005-05-24 | 2010-09-15 | Flamel Tech Sa | Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung |
US20080075771A1 (en) * | 2006-07-21 | 2008-03-27 | Vaughn Jason M | Hydrophilic opioid abuse deterrent delivery system using opioid antagonists |
PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
WO2008085674A1 (en) * | 2007-01-04 | 2008-07-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions comprising celecoxib co-crystals |
WO2009063367A1 (en) * | 2007-11-15 | 2009-05-22 | Pfizer Products Inc. | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
EP2105130A1 (de) * | 2008-03-25 | 2009-09-30 | Ratiopharm GmbH | Pharmazeutische Formulierung und Verfahren zu deren Herstellung |
EP2133068A1 (de) * | 2008-06-13 | 2009-12-16 | Ratiopharm GmbH | Verfahren zur Auswahl eines geeigneten Hilfsstoffs für die Herstellung von festen Dispersionen für pharmazeutische Formulierungen |
ES2855426T3 (es) * | 2008-09-17 | 2021-09-23 | Mylan Inc | Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen |
RU2526914C2 (ru) * | 2009-06-19 | 2014-08-27 | Наноформ Хунгари Лтд. | Композиции телмисартана в форме наночастиц и способ их получения |
WO2010150144A2 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Low dose pharmaceutical compositions of celecoxib |
WO2011055233A2 (en) | 2009-11-03 | 2011-05-12 | Actavis Group Ptc Ehf | Improved process for preparing celecoxib polymorph |
US20110213159A1 (en) * | 2010-03-01 | 2011-09-01 | Vamsee Krishna Muppidi | Process for preparation of celecoxib crystalline form |
CN102764264A (zh) * | 2012-07-25 | 2012-11-07 | 杭州和泽医药科技有限公司 | 一种具高溶出度的塞来昔布固体组合物、制备方法及应用 |
CN103655478A (zh) * | 2012-09-26 | 2014-03-26 | 北京星昊医药股份有限公司 | 一种塞来昔布固体分散体及其制备方法和应用 |
US9352047B2 (en) | 2012-11-14 | 2016-05-31 | Abon Pharmaceuticals, Llc | Oral transmucosal drug delivery system |
JP6304896B2 (ja) * | 2013-07-30 | 2018-04-04 | ライオン株式会社 | 錠剤 |
RU2016142819A (ru) * | 2014-04-03 | 2018-05-10 | Сандоз Аг | Твердая композиция, содержащая аморфный софосбувир |
KR101994129B1 (ko) * | 2015-05-28 | 2019-06-28 | 닥터 레디스 레보러터리즈 리미티드 | 통증 치료를 위한 셀레콕시브 경구용 조성물 |
US20180271890A1 (en) * | 2015-10-07 | 2018-09-27 | Sandoz Ag | Solid Pharmaceutical Composition Comprising Amorphous Sofosbuvir |
HUP1500618A2 (en) | 2015-12-16 | 2017-06-28 | Druggability Tech Ip Holdco Ltd | Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them |
WO2018031577A1 (en) * | 2016-08-09 | 2018-02-15 | Autotelic Llc | Fixed dose combination for pain relief without edema |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
KR102002906B1 (ko) * | 2016-10-18 | 2019-07-23 | 경동제약 주식회사 | 셀레콕시브를 포함하는 정제 |
US10080762B2 (en) | 2016-12-14 | 2018-09-25 | Druggability Technologies Ip Holdco Limited | Pharmaceutical composition containing Celecoxib |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
WO2020214791A1 (en) * | 2019-04-18 | 2020-10-22 | Nangenex Nanotechnology Incorporated | Celecoxib compositions and methods for their use |
CN111505058A (zh) * | 2020-03-05 | 2020-08-07 | 艾普康(香港)有限公司 | 乳房炎检测分析仪 |
CN112358492B (zh) * | 2020-11-13 | 2022-04-15 | 兰州大学 | 碳硼烷基塞来昔布及其制备和在头颈癌硼中子俘获治疗药物中的应用 |
KR102459968B1 (ko) * | 2022-01-21 | 2022-10-27 | 주식회사 큐어팜텍 | 기능성 약물이 함유된 생분해성 수지 제조방법 및 이에 의해 제조된 생분해성 수지 |
CN116942630B (zh) * | 2023-09-19 | 2023-12-26 | 北京福元医药股份有限公司 | 一种塞来昔布胶囊剂及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
JPS60139688A (ja) * | 1983-12-28 | 1985-07-24 | Tokyo Tanabe Co Ltd | 無定形ジヒドロピリジン粉末製剤 |
CN1061036C (zh) * | 1993-11-30 | 2001-01-24 | G·D·瑟尔公司 | 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物 |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
CA2222138C (en) * | 1995-05-25 | 2008-10-14 | G.D. Searle & Co. | Method of preparing 3-haloalkyl-1h-pyrazoles |
WO1998019708A2 (en) | 1996-11-04 | 1998-05-14 | Union Carbide Chemicals & Plastics Technology Corporation | Method for enhancing the solubility of substantially water-insoluble compounds |
KR100187959B1 (ko) * | 1997-03-31 | 1999-06-01 | 윤재승 | 저융점 무정형 세푸록심 악세틸의 제조방법 |
SE9802333D0 (sv) * | 1998-06-29 | 1998-06-29 | Astra Pharma Prod | Novel combination |
AU759307B2 (en) * | 1998-11-02 | 2003-04-10 | Merck Sharp & Dohme Corp. | Method of treating migraines and pharmaceutical compositions |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
EP1144383A1 (en) | 1999-01-14 | 2001-10-17 | Merck Frosst Canada & Co. | Synthesis of 4-[(5-substituted or unsubstituted phenyl)-3-substituted-1h-pyrazol-1-yl]benzenesulfonamides |
AU4308300A (en) * | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
GB9920558D0 (en) | 1999-08-31 | 1999-11-03 | Bradford Particle Design Ltd | Methods for particle formation and their products |
CN1376146B (zh) * | 1999-12-08 | 2011-04-06 | 法马西亚公司 | 提高了生物利用率的雪列柯西的固态形式 |
US6864373B2 (en) * | 2002-05-13 | 2005-03-08 | Pharmacia Corporation | Stable amorphous celecoxib composite and process therefor |
-
2000
- 2000-12-06 CN CN008056358A patent/CN1376146B/zh not_active Expired - Fee Related
- 2000-12-06 BR BR0008058-6A patent/BR0008058A/pt not_active Application Discontinuation
- 2000-12-06 CA CA002362673A patent/CA2362673A1/en not_active Abandoned
- 2000-12-06 ES ES00982255T patent/ES2299441T3/es not_active Expired - Lifetime
- 2000-12-06 EP EP00982255A patent/EP1150959B1/en not_active Revoked
- 2000-12-06 US US09/730,663 patent/US6964978B2/en not_active Expired - Lifetime
- 2000-12-06 IL IL14476100A patent/IL144761A0/xx active IP Right Grant
- 2000-12-06 HU HU0201450A patent/HUP0201450A3/hu unknown
- 2000-12-06 DE DE60038162T patent/DE60038162T2/de not_active Expired - Lifetime
- 2000-12-06 AT AT00982255T patent/ATE387431T1/de active
- 2000-12-06 WO PCT/US2000/032435 patent/WO2001042221A1/en active IP Right Grant
- 2000-12-06 NZ NZ513964A patent/NZ513964A/xx not_active IP Right Cessation
- 2000-12-06 SK SK1268-2001A patent/SK12682001A3/sk not_active Application Discontinuation
- 2000-12-06 EA EA200100873A patent/EA003612B1/ru not_active IP Right Cessation
- 2000-12-06 DK DK00982255T patent/DK1150959T3/da active
- 2000-12-06 PL PL349223A patent/PL203262B1/pl not_active IP Right Cessation
- 2000-12-06 AU AU19311/01A patent/AU784572B2/en not_active Ceased
- 2000-12-06 JP JP2001543522A patent/JP2004500358A/ja active Pending
-
2001
- 2001-08-06 IL IL144761A patent/IL144761A/en unknown
- 2001-08-08 NO NO20013855A patent/NO320844B1/no not_active IP Right Cessation
-
2005
- 2005-07-26 US US11/189,659 patent/US7220867B2/en not_active Expired - Lifetime
-
2007
- 2007-05-04 US US11/744,603 patent/US20070202160A1/en not_active Abandoned
-
2008
- 2008-04-10 CY CY20081100393T patent/CY1107389T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL144761A0 (en) | 2002-08-14 |
NO20013855L (no) | 2001-10-05 |
CN1376146A (zh) | 2002-10-23 |
IL144761A (en) | 2007-07-24 |
AU784572B2 (en) | 2006-05-04 |
WO2001042221A1 (en) | 2001-06-14 |
BR0008058A (pt) | 2002-03-26 |
US20070202160A1 (en) | 2007-08-30 |
PL203262B1 (pl) | 2009-09-30 |
CY1107389T1 (el) | 2012-12-19 |
ATE387431T1 (de) | 2008-03-15 |
EA003612B1 (ru) | 2003-06-26 |
NO320844B1 (no) | 2006-02-06 |
JP2004500358A (ja) | 2004-01-08 |
HUP0201450A2 (hu) | 2002-12-28 |
US7220867B2 (en) | 2007-05-22 |
US6964978B2 (en) | 2005-11-15 |
EP1150959A1 (en) | 2001-11-07 |
DE60038162T2 (de) | 2009-02-26 |
US20050267190A1 (en) | 2005-12-01 |
DE60038162D1 (de) | 2008-04-10 |
SK12682001A3 (sk) | 2002-07-02 |
ES2299441T3 (es) | 2008-06-01 |
NZ513964A (en) | 2004-01-30 |
EP1150959B1 (en) | 2008-02-27 |
CA2362673A1 (en) | 2001-06-14 |
EA200100873A1 (ru) | 2002-02-28 |
CN1376146B (zh) | 2011-04-06 |
NO20013855D0 (no) | 2001-08-08 |
PL349223A1 (en) | 2002-07-01 |
AU1931101A (en) | 2001-06-18 |
US20020006951A1 (en) | 2002-01-17 |
HUP0201450A3 (en) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1150959T3 (da) | Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed | |
MY128971A (en) | Solid-state form of celecoxib having enhanced bioavailability | |
NO20051966L (no) | Nye pyrimidinamidderivater og anvendelse derav | |
ME00181B (me) | Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primjena | |
WO2003088958A3 (en) | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease | |
DE60022525D1 (de) | Ramipril zur vorbeugung von kardiovaskulären vorfällen | |
NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
WO2008021113A3 (en) | Transdermal methods and systems for treating alzheimer's disease | |
BRPI0507628A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto | |
EP1140840A4 (en) | DIPHENYLUREA WITH SUBSTITUENTS -G (V) -CARBOXYARYLES, INHIBITORS OF RAF KINASE | |
MX2009001130A (es) | Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos. | |
WO2005011586A3 (en) | Treatment and preventi0n of cardiovascular events | |
ATE505464T1 (de) | Feste form von amg 706 und pharmazeutische zusammensetzungen davon | |
WO2002007721A3 (en) | Use of cox-2 inhibitors for preventing immunodeficiency | |
JOP20220075A1 (ar) | مثبطات عامل d المكمل عن طريق الفم | |
JOP20220077A1 (ar) | مثبطات عامل d المكمل عن طريق الفم | |
DE69315699D1 (de) | Inhibitoren gegen die aggregation von blutplättchen | |
DE602007010734D1 (de) | Hydratformen von amg706 | |
WO2005081972A3 (en) | Maleiimide anti-tumor phosphatase inhibitors | |
WO2003101380A3 (en) | Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors | |
ECSP003813A (es) | Forma de estado solido de celecoxib con una mejora en la biodisponibilidad | |
DE60028787D1 (de) | Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten | |
WO2006077139A3 (en) | Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same | |
HUP0302882A2 (hu) | Javított specificitás betegségek kezelésében | |
WO2003066806A3 (en) | Therapeutic use of aziridino compounds |